| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -21.7 | -13.3 |
| EPS (diluted, $ a share) | $-0.35 | $-0.31 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: TARA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Protara Therapeutics, Inc.: key numbers
- Share price
- $2.38Close, Nov 16
- Market cap
- $147M
- Shares outstanding
- 61.57MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Protara Therapeutics, Inc.
All →Protara Therapeutics Financial Results
Protara Therapeutics reported third quarter 2026 financial results and provided a clinical pipeline update, including the expected completion of enrollment for its TARA-002 registrational cohort in NMIBC by year-end. The company also announced an $8.75 million asset purchase agreement with Novex Innovations for manufacturing-related assets and reported a cash position of $143 million, sufficient to fund operations into 2028.
“Protara continues to deliver across our late-stage portfolio, advancing each of our programs toward its next key clinical and regulatory milestone. This steady progress positions us to close out the year with strong momentum and sets the stage for an impactful 2027.”
Jesse Shefferman, Chief Executive Officer at Protara Therapeutics
“TARA-002 has the potential to be a preferred treatment option for patients with non-muscle invasive bladder cancer (NMIBC), and we are on track to complete enrollment of the BCG-Unresponsive registrational cohort by year-end, a key step toward bringing this therapy to patients.”
Jesse Shefferman, Chief Executive Officer at Protara Therapeutics